Forest Laboratories entered into an agreement with Gedeon Richter for Gedeon’s RGH-188, an orally active potent D2/D3 antagonist that has entered into phase 1 clinical trials. The analyst opinion article states that Gedeon Richter is gaining the financial help with the development of the compound, though RGH-188 is still many years away from the market and will not translate into returns for the foreseeable future to Forest.